Biden Administration’s $3.5 Billion Purchase Agreement with Pfizer for International Vaccine Donation

On September 22, 2021, Knowledge Ecology International (KEI) obtained a copy of the $3.5 billion contract between the U.S. government and Pfizer to purchase 500 million doses of the Pfizer/BioNTech vaccine for international donation to low- and middle-income countries. The… Continue Reading

Texas A&M Vaccine Manufacturing Contract Shows that cGMP Manufacturing of COVID-19 Vaccines Can Start in Five Months 

A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading

Fissures on intellectual property, C-TAP and transparency emerge in WHO local production negotiations

On 4 December 2020, Ethiopia submitted a Zero Draft resolution to the World Health Organization (WHO) on Strengthening Local Production of Medicines and Other Health Technologies to Improve Access – WHO Resolution on Strengthening Local Production of Medicines and Other… Continue Reading

$1.3 Billion Johnson & Johnson COVID-19 Vaccine Development Contract Contains Broad Redactions Relating to Public’s Rights in Inventions

On March 31, 2020, KEI received a copy of the contract between Johnson & Johnson (“J&J”) and the Department of Health and Human Services (HHS) for the development of J&J’s COVID-19 vaccine.The contract, which is now valued at $1.3 billion,… Continue Reading

Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights

KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading

Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products

One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading

EB 148: KEI’s statement on WHO’s Global Observatory on Health R&D

On Friday, 22 January 2021, Knowledge Ecology International delivered the following remarks on WHO”s Global Observatory on Health R&D at the 148th session of WHO’s Executive Board. At meetings of WHO governing bodies, non-State actors are limited to one minute… Continue Reading

Letter from the People’s Vaccine Alliance and Health Action International to Dr. Tedros on C-TAP

On 21 January 2021 the People’s Vaccine Alliance and Health Action International (HAI) sent an open letter to Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), expressing concern about the lack of political support and reported progress… Continue Reading

WHO informal consultation (3 December 2020) addressed concerns on price transparency and shortages

On Monday, 11 January 2021, the secretariat of the World Health Organization (WHO) published an 18 page report on the Global strategy and plan of action on public health, innovation and intellectual property (EB148/10). The Director-General’s report contains a detailed… Continue Reading